Gilead Sciences Gets Initial OK On $247M HIV Antitrust Deal
A California federal judge on Thursday granted preliminary approval to Gilead's deal to pay the direct purchasers of its HIV medications $246.8 million to end claims the pharmaceutical company cut a...To view the full article, register now.
Already a subscriber? Click here to view full article